[go: up one dir, main page]

MX2019011026A - Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. - Google Patents

Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.

Info

Publication number
MX2019011026A
MX2019011026A MX2019011026A MX2019011026A MX2019011026A MX 2019011026 A MX2019011026 A MX 2019011026A MX 2019011026 A MX2019011026 A MX 2019011026A MX 2019011026 A MX2019011026 A MX 2019011026A MX 2019011026 A MX2019011026 A MX 2019011026A
Authority
MX
Mexico
Prior art keywords
novel
dna vaccine
cancer immunotherapy
targeting dna
salmonella
Prior art date
Application number
MX2019011026A
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of MX2019011026A publication Critical patent/MX2019011026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4562—Salmonella; Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una cepa atenuada de Salmonella que comprende al menos una copia de una molécula de ADN que comprende un casete de expresión que codifica PD-L1. En particular, la presente invención se refiere a dicha cepa atenuada de Salmonella para su uso en el tratamiento del cáncer.
MX2019011026A 2017-03-17 2018-03-16 Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. MX2019011026A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161666 2017-03-17
EP17188941 2017-09-01
PCT/EP2018/056721 WO2018167290A1 (en) 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
MX2019011026A true MX2019011026A (es) 2020-12-10

Family

ID=61627121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011026A MX2019011026A (es) 2017-03-17 2018-03-16 Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.

Country Status (13)

Country Link
US (2) US11357842B2 (es)
EP (1) EP3595704A1 (es)
JP (2) JP7247097B2 (es)
KR (1) KR20190125481A (es)
CN (1) CN110430893A (es)
AU (1) AU2018235153A1 (es)
BR (1) BR112019019251A2 (es)
CA (1) CA3056807A1 (es)
IL (1) IL268677A (es)
MX (1) MX2019011026A (es)
RU (1) RU2019132253A (es)
SG (1) SG11201908528UA (es)
WO (1) WO2018167290A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210042655A (ko) 2019-10-10 2021-04-20 주식회사 엘지화학 히팅 패드 제어 장치
CA3162994A1 (en) 2020-01-13 2021-07-22 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
CU24705B1 (es) 2020-10-22 2024-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1
CN115645520A (zh) * 2022-11-15 2023-01-31 中国科学技术大学 一种化疗诱导的肿瘤蛋白抗原纳米疫苗的制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0584266T3 (da) * 1991-05-06 2003-12-29 Us Gov Health & Human Serv Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
EP2328920A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2850245C (en) * 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
EP2869836B1 (en) 2012-07-05 2019-09-25 Vaximm AG Dna vaccine for use in pancreatic cancer patients
CA2910213A1 (en) * 2013-04-25 2014-10-30 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
TWI676636B (zh) * 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
JP6662787B2 (ja) * 2013-12-18 2020-03-11 バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン
AU2015205342B2 (en) * 2014-01-07 2020-01-23 Babita Agrawal Immunomodulatory compositions and methods of use thereof
DK3310379T3 (da) 2015-06-18 2019-12-16 Vaximm Ag Vegfr-2-targeterende dna-vaccine til kombinationsterapi
US20180153976A1 (en) * 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
SG11201908528UA (en) 2019-10-30
IL268677A (en) 2019-10-31
KR20190125481A (ko) 2019-11-06
CN110430893A (zh) 2019-11-08
US11357842B2 (en) 2022-06-14
RU2019132253A (ru) 2021-04-19
BR112019019251A2 (pt) 2020-04-28
WO2018167290A1 (en) 2018-09-20
CA3056807A1 (en) 2018-09-20
JP2023021116A (ja) 2023-02-09
JP7247097B2 (ja) 2023-03-28
EP3595704A1 (en) 2020-01-22
JP2020511139A (ja) 2020-04-16
US20220273782A1 (en) 2022-09-01
AU2018235153A1 (en) 2019-10-31
US20200085928A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
CY1125385T1 (el) Συστημα πολλαπλων φορεων και χρησεις αυτου
MX2015014851A (es) Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer.
MX2022001105A (es) Anticuerpos anti tigit.
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
CY1124564T1 (el) Εξασθενημενης λοιμογονικοτητας βακτηριδια για θεραπεια κακοηθων συμπαγων ογκων
MX2014015977A (es) Vacuna de adn para usarse en pacientes con cancer pancreatico.
MX2019011026A (es) Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.
MY191539A (en) Streptococcal vaccine
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2018005467A (es) Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
MX2017001650A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen
EA202090107A3 (ru) Композиции, содержащие бактериальные штаммы
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MA39900A (fr) Vaccins à base d'acide nucléique
UA91603U (uk) Спосіб лікування обмеженої склеродермії